Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololBjörn Dahlöf, Hans Wedel, Richard B. Devereux et al.|The Lancet|2002Cited by 5.4k
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trialPeter Sever, Jan Östergren, Björn Dahlöf et al.|The Lancet|2003Cited by 3.8k
ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008Kenneth Dickstein, Gerasimos Filippatos, John J.V. McMurray et al.|European Journal of Heart Failure|2008Cited by 3.5k
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trialBjörn Dahlöf, Jan Östergren, Hans Wedel et al.|The Lancet|2005Cited by 2.9k
Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololLars Lindholm, Steven Snapinn, Hans Ibsen et al.|The Lancet|2002Cited by 1.6k